VivoSeq
Neurology

Intracranial Hemorrhage

14

Pipeline Programs↗

4

Active Trials↗

9

Companies Involved↗

Intracranial Hemorrhage is an emerging landscape with 14 programs across 9 companies. The most active players are CSL Behring, Roche, Bristol-Myers Squibb. 3 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

60/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

CSL Behring logo

CSL Behring

2 programs

Phase 1Roche logo

Roche

2 programs

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 3Sanofi logo

Sanofi

1 program

Phase 3Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

ApprovedDaiichi Sankyo logo

Daiichi Sankyo

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

87%

Small molecule

13 of 15 classified programs — the dominant modality here.

13%ALL OTHERSMonoclonal antibody17%Protein / enzyme17%

Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 100% of 16 pipeline programs.

Analysis

Trial Status

13

clinical trials

Unknown status4 · 31%
Completed3 · 23%
Not yet recruiting2 · 15%
Terminated1 · 8%
Withdrawn1 · 8%
Active, not recruiting1 · 8%
Other1 · 8%

Clinical Trials

Trial Activity

13 trials

China Research for Severe Spontaneous Intracerebral Hemorrhage（CRISIH）
Recruiting·BBeijing Tiantan Hospital·N/A·NCT05975398·2,000 enrolled
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
Active, not recruiting·PPopulation Health Research Institute·Phase 4·NCT03950076·948 enrolled
Restarting Anticoagulation After Traumatic Intracranial Hemorrhage
Not yet recruiting·UUniversity of Texas at Austin·Phase 3·NCT04229758·1,100 enrolled
Intracranial Hemorrhage Risk of Intensive Statin in Acute Ischemic Stroke With Cerebral Microbleeds
Not yet recruiting·SSichuan Provincial People's Hospital·Phase 4·NCT05589454·344 enrolled
Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage
Completed·NNICHD Neonatal Research Network·Phase 3·NCT00009620·610 enrolled
Registration of Idarucizumab for Patients with IntraCranial Hemorrhage
Completed·UUniversity Hospital, Essen·N/A·NCT04062097·104 enrolled
Risk of Intracranial Hemorrhage in Users of Oral Antithrombotic Drugs
Completed·SSt. Olavs Hospital·N/A·NCT02481011·22,111 enrolled
Factor VII, Prothrombin Complex Concentrate, and Fresh Frozen Plasma in Warfarin-Related Intracranial Hemorrhage
Terminated·UUniversity of Utah·Phase 1·NCT00770718·2 enrolled
FFP Versus PCC in Intracranial Hemorrhage
Withdrawn·UUniversity of Utah·N/A·NCT02429453
Intravenous Immunoglobulin for Acute Intracranial Hemorrhage
Unknown status·—·Phase 2·NCT02782897·60 enrolled
Relationships Among FVIII, t-PA/PAI-1, and MMP-9 Levels and Intracranial Hemorrhage Complications After Thrombolysis With Alteplase in Patients With Acute Ischemic Stroke: Protocol for a Multicenter Retrospective Study
Unknown status·ZZhujiang Hospital·N/A·NCT03733223·350 enrolled
Restart TICrH Alpha Pilot Protocol, Restarting DOACs After Traumatic Intracranial Hemorrhage
Unknown status·UUniversity of Texas at Austin·Phase 3·NCT04891861·100 enrolled
Anticoagulant-associated Intracranial Hemorrhage
Unknown status·EEl Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez·N/A·NCT06168838·1,200 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)